Participate in a research study at PRC: Newcastle
Our new modern research facility is easily accessible for patients and parking. Here you will receive a warm welcome from our friendly and professional team. We offer a number of ways to make it easier to take part in a research study, including extended hours, video consultations and virtual trials (where you don’t need to attend in person).
On this page you can find out about studies we are currently delivering, upcoming studies, and studies that we have delivered in the past.
Open studies that are accepting new participants
These studies are currently seeking new participants. Use the links below to access more information about each study.
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
20170703 is a study in adult participants with Chronic Migraine (CM) and Medication Overuse Headache (MOH). The purpose of conducting the study is to better understand the effectiveness and safety of erenumab compared to placebo when given to a targeted population diagnosed with CM and MOH that have at least one preventative treatment failure, to see if it makes any changes in the number of days participants suffer from monthly headache days (MHD) and are able to revert the medication overuse status.
This study aims to provide evidence of routine treatment with Ajovy® (fremanezumab) in clinical practice. It intends to obtain information on treatment effectiveness and factors influencing effectiveness, severity of the migraine attacks, migraine and non-migraine medication use, injection intervals and the duration of Ajovy® treatment.
Eptinezumab in patients with episodic Cluster Headache
The purpose of this study is to determine if the study medication, eptinezumab, is safe and effective as treatment for those who suffer from episodic Cluster Headache. Eptinezumab is a humanised monoclonal antibody (a type of antibody made in the laboratory).
The purpose of the study is to evaluate how effective dupilumab is and how safe it is in reducing the signs and symptoms in participants with chronic spontaneous urticaria (CSU) who continue to have symptoms despite the use of H1-antihistamines (H1AH).
Efficacy and Safety of Molnupiravir in Non-Hospitalized Adult Participants With COVID-19
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29.
These studies are currently being planned. Where possible, we have tried to indicate when the study may open for participants. Check this page frequently for updates.
CORVIS (COPD) trial
The CORVIS trial is investigating the use of a new drug (inhaled via a handheld nebuliser to produce nitric oxide in the lungs) for treatment of infective exacerbations of COPD and bronchiectasis. Nitric oxide plays a key part in our body’s own defence against microbial infection in the lungs and has already been approved for use in the treatment of lung disease in neonates. In this study it will be used in addition to the usual treatment you would receive during an infective exacerbation, such as oral steroids and antibiotics.
- Learn more about the CORVIS (COPD) trial by reading the Participant Information Sheet
- Additional CORVIS information
The purpose of the study is to investigate the effect, safety, and tolerability of the study drug for the treatment of patients with COPD, who continue to have symptoms on current treatment, and who are in need of an additional treatment to their current COPD management (standard of care SoC ). Simply put, we want to see if adding the drug on top of your current treatments improves COPD outcomes/exacerbations, therefore this study treatment will be given in addition to your current controller therapy.
GSK3511294 (also called the “study drug”) is being tested as a potential new medicine for severe asthma and is not yet approved to treat patients with asthma. The study drug is a type of medicine called a monoclonal antibody that is made in the
laboratory. It works by blocking a specific protein in the body called interleukin-5 which is involved in the severity of asthma and inflammation of the lungs.
These studies are no longer seeking new patients. Where possible, we will update the information links below when the study findings are published and with related information.
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
This study is testing a treatment called remdesivir to understand if it can help prevent or reduce hospitalization of people with early stage COVID-19.
- Visit the Be Part of Research website to learn more about the Remdesivir as a COVID-19 outpatient treatment study.
Enterosgel® in the treatment of Irritable Bowel Syndrome with diarrhoea (RELIEVE IBS-D study)
The RELIEVE IBS-D trial is testing a new treatment for Irritable Bowel Syndrome with Diarrhoea (IBS-D).
The MANDALA study is investigating a new drug for people who are currently living with moderate to severe asthma.